All In Biotech

Drug Trial Radar · NCT02799706

Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer

Phase IIIb Randomized Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer. A Joint Study of the EORTC ROG and GUCG

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 885 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

885

Planned (sponsor's estimate)

Start

Sep 25, 2017

Primary completion

Aug 23, 2023

Study completion Jun 30, 2026

Sponsor

Sponsor type
Research network
First posted
Jun 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the trial is to assess if GnRH antagonists in combination with external beam radiation therapy improve progression free survival (progression that can be biological, clinical, or death) compared to GnRH agonists in combination with external beam radiation therapy. Secondary objectives include: * documentation of effect of GnRH antagonists on clinically significant cardiovascular events in the subgroup of patients at high risk of such events at baseline; * documentation of side effects and quality of life, I-PSS and urinary tract infections; * assessment of relative treatment effect on secondary efficacy endpoints (clinical progression, time to next line of systemic therapy, time on therapy, overall and cancer specific survival) and on PSA at 6 months after end of RT.

Conditions

  • Prostate Cancer

Interventions

  • DegarelixDrug

    a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy

  • approved GnRH agonistDrug

    A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm.

  • RadiotherapyRadiation

    .As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survivalTime frame: through study completion, an average of 1 year

Locations

39 sites in 8 countries. Site status is shown where the registry gives one.

  • Hopitaux Universitaires Bordet-Erasme - Hopitaux Universitaires Bordet- Institut Jules Bordet

    Brussels, Belgium

  • Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme

    Brussels, Belgium

  • Universitair Ziekenhuis Brussel

    Brussels, Belgium

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Hopital De Jolimont

    Haine-Saint-Paul, Belgium

  • AZ Groeninge Kortrijk - Campus Kennedylaan

    Kortrijk, Belgium

  • CHU Ucl Namur - Site Sainte-Elisabeth

    Namur, Belgium

  • Gasthuiszusters van Antwerpen - GasthuisZusters Antwerpen - Sint-Augustinus

    Wilrijk, Belgium

  • University Hospitals Copenhagen - Rigshospitalet

    Copenhagen, Denmark

  • Clinique de l'Europe

    Amiens, France

  • Centre de radiotherapie Marie Curie

    Arras, France

  • Centre D'Onco. & Radioth. De Haute Energie Du Pays Basque

    Bayonne, France

  • Groupe Radiopole Artois - Centre de Radiotherapie Pierre Curie

    Beuvry, France

  • CHU de Grenoble - La Tronche - Hôpital A. Michallon

    Grenoble, France

  • Centre Leon Berard

    Lyon, France

  • Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau

    Nantes, France

  • Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere

    Paris, France

  • Centre Hospitalier Privé Saint-Grégoire

    Saint-Grégoire, France

  • Clinique Pasteur-Toulouse-Atrium

    Toulouse, France

  • Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin

    Berlin, Germany

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Otto-Von-Guericke-Universitaet Magdeburg - Universitaetsklinik

    Magdeburg, Germany

  • Azienda Ospedaliero-Universitaria Careggi

    Florence, Italy

  • AUSL Romagna - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

    Meldola, Italy

  • Fundacion Hospital Alcorcon

    Alcorcón, Spain

  • Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia)

    Barcelona, Spain

  • Clinica IMQ Zorrotzaurre

    Bilbao, Spain

  • Hospital General Universitario Santa Lucia

    Cartagena, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Spain

  • Hospital Universitario de Gran Canaria Doctor Negrin

    Las Palmas de Gran Canaria, Spain

  • Complejo Hospitalario A

    Pamplona, Spain

  • Corporacio Sanitaria Parc Tauli

    Sabadell, Spain

  • Hospital Universitario de Salamanca

    Salamanca, Spain

  • Hospital Consorci Sanitari De Terrassa

    Terrassa, Spain

  • Complejo Hospitalario Universitario de Vigo -CHUVI - Hospital Alvaro Cunqueiro

    Vigo, Spain

  • Oncology Institute of Southern Switzerland (IOSI) - Oncology Institute of Southern Switzerland - Ospedale Regionale Bellinzona e Valli

    Bellinzona, Switzerland

  • Inselspital

    Bern, Switzerland

  • Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie

    Geneva, Switzerland

  • Nottingham University Hospitals NHS Trust - City Hospital

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.